Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group.

Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, Lecorre D, Helias-Rodzewicz Z, Hofman P, Sabourin JC, Laurent-Puig P.

Abstract

BACKGROUND:

Knowledge about tumour gene mutation status is essential for the treatment of increasing numbers of cancer patients, and testing quality has a major impact on treatment response and cost. In 2012, 4,629 tests for BRAF p.V600 were performed in France, in patients with melanomas.

METHODS:

Two batches of unstained melanoma sections were sent, in May and November 2012, to the 46 laboratories supported by the French National Institute of Cancer (INCa). An external quality assessment (EQA) evaluated mutation status, response times and compliance with INCa recommendations.

RESULTS:

All the French laboratories involved in testing participated in the EQA. Fourteen different methods were used to detect BRAF mutations, most consisting of combinations of in-house techniques. False responses were noted in 25/520 cases (4.8%), 11 of which concerned confusion between p.V600E and p.V600K. Thus, 2.7% of responses would have led to inappropriate treatment. Within six months, mean response times decreased from 22 to 12 days (P<0 .001="" 75.2="" 96.9="" a="" and="" by="" cell="" content="" evaluated="" for="" from="" increased="" of="" p="" pathologist="" percentage="" samples="" the="" to="" tumour="">

CONCLUSION:

Despite the use of non-certified methods, the false response rate was low. Nationwide EQA can improve the quality of molecular pathology tests on tumours.